Pharmacological action Catapres-TTS 1, 2, 3 Patch
Catapres-TTS Patch Antihypertensive medication central action, stimulates postsynaptic alpha 2-adrenergic receptors in the vasomotor center of medulla oblongata and reduces the flow of sympathetic impulses to the vessels and heart at the presynaptic level. Reduces the PR and the IOC, slows heart rate. At fast / in a possible short-term increase in blood pressure caused by stimulation of postsynaptic alpha 1-adrenergic receptors of blood vessels. Increases renal blood flow, increasing the tone of cerebral blood vessels, reduces cerebral blood flow, has a marked sedative effect.
The duration of therapeutic effect – 6-12 hours
Pharmacokinetics Catapres-TTS 1, 2, 3 Patch
Absorption after oral administration – fast. Bioavailability of long-term use – about 65%. TCmax after oral administration – 1.5-2.5 hours, with the use of TTC – 2-3 days. Relationship to plasma proteins – 20-40%. Quickly and easily penetrates the blood-brain barrier, placenta and breast milk.
Metabolized by the liver (about 50% of the drug has grown deep). Excreted by the kidneys (40-60%) and through the intestine (20%). T1 / 2 – 12-16 hours, with impaired renal function – up to 41 hours
Precautions Catapres-TTS 1, 2, 3 Patch
Recent myocardial infarction, chronic renal failure.
Dosage and Catapres-TTS 1, 2, 3 Patch
Inside, regardless of the meal, the initial dose of 0.075 mg three times a day. If necessary, gradually increase the dose to an average daily dose of 0.9 mg. The maximum single dose is 0.3 mg, maximum daily dose – 2.4 mg.
Elderly patients, especially if the manifestations of cerebrovascular disease, prescribed an initial dose – 0.0375 mg 3 times a day.
Remove the drug is carried out gradually over 1-2 weeks.
As a means of preventing the headache of vascular origin: oral, 0.025 mg 2-4 times a day, if necessary, increase the dose to 0.05 mg 3 times a day.
If dysmenorrhea: oral, 0.025 mg 2 times a day for 14 days prior to and during menstruation.
As an auxiliary drug in the treatment of vegetative symptoms of menopause: inside, at 0.025-0.075 mg 2 times a day.
For relief of hypertensive crisis – sublingual (in the absence of severe dry mouth) or in / or / m at a dose of 0.15 mg.
For I / O jet injection of 1 ml diluted in 10 ml 0.9% NaCl and injected within 7-10 minutes.
For in / drip 4 ml of solution diluted in 500 ml 5% dextrose and injected with an average speed of 20 drops / min. The maximum infusion rate – 120 drops / min.
Contra Catapres-TTS 1, 2, 3 Patch
Hypersensitivity, depression, marked cerebral atherosclerosis, obliterating diseases of arteries, arterial hypotension, marked sinus bradycardia, SSS, AV block II-III century., Cardiogenic shock, concomitant use of tricyclic antidepressants and ethanol, pregnancy, lactation.
Indications for use Catapres-TTS 1, 2, 3 Patch
Hypertension (including symptomatic hypertension on the basis of renal disease), hypertensive crisis, acute myocardial infarction (in the absence of cardiogenic shock), pheochromocytoma (diagnosis) and headache of vascular origin (prevention), dysmenorrhea, or menopause (the treatment of vasomotor symptoms ), nicotine dependence, the syndrome of Gilles de la Tourette, the withdrawal syndrome in drug addicts (in the complex therapy).
Side effects Catapres-TTS 1, 2, 3 Patch
From the digestive system: dry mouth, decreased appetite, nausea, vomiting, constipation, decreased gastric secretion.
Nervous system disorders: asthenia, somnolence, slowing of mental and motor responses, anxiety, nervousness, depression, vivid or “nightmarish” dream.
From the CCC: bradycardia, orthostatic hypotension, with a / in the introduction – increased blood pressure (short).
Genitourinary: reduced potency and / or libido.
Allergic reactions: skin rash, itching.
Other: Raynaud’s syndrome, a delay of Na + and water, manifested by swelling of the feet and ankles, nasal congestion, with the sudden cancellation – the syndrome of “cancellation”, “gemitonovy crisis.”
An overdose of Catapres-TTS 1, 2, 3 Patch
Symptoms (toxic effects can occur in children receiving 0.1 mg) reduced blood pressure or increased blood pressure (especially in children), bradycardia, broadening complex QRS, AV conduction delay, early repolarization syndrome, lethargy, miosis, hypothermia, respiratory depression (possibly until apnea) collapse, impaired consciousness.
Treatment: symptomatic.
Cautions Catapres-TTS 1, 2, 3 Patch
Currently, clonidine is displaced from the general practice of the sharp but short-term reduction of blood pressure with subsequent phase of increasing blood pressure (“gemitonovye crises”).
In acute myocardial infarction, as well as for treatment of vasomotor symptoms in the face of dysmenorrhea and menopause, withdrawal syndrome in drug addicts and labile hypertension during his appointment is particularly desirable. In these cases, preferable to imidazoline receptor agonists.
With long-term parenteral administration of clonidine should regularly monitor the intraocular pressure.
For the prevention of orthostatic hypotension with / in the introduction, the patient should be in a horizontal position during and for 1.5-2 h after injection.
Perhaps the development of weakly positive Coombs’ reaction.
During the period of treatment must be careful when driving and occupation of other potentially hazardous activities that require your full attention and psychomotor speed of reaction.
Description Catapres-TTS 1, 2, 3 Patch
White crystalline powder. Soluble in water, slightly soluble in ethanol, chloroform and ether.
Interaction Catapres-TTS 1, 2, 3 Patch
Enhances the action of drugs which depress the central nervous system, and ethanol.
Amplify the effect of other vasodilators, diuretics, antihistamines and drugs, weaken – tricyclic antidepressants, anorectics drugs (with the exception of fenfluramine – increases), NSAIDs and sympathomimetic.
Beta-blockers and / or cardiac glycosides increase the risk of bradycardia and AV block.
